[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adaptive-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adaptive-treatment":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100587624",false,"NCT06930807","Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer","Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer","Inclusion Criteria:\n\n* Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy\n* Solid nodules \\>1 cm or ground-glass nodules \\>1.5 cm on imaging\n* No history of malignancies other than non-small cell lung cancer in the past 5 years\n* Specimens are well preserved and imaging documents are accessible.\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)\n* Pathology results confirmed not to be non-small cell lung cancer\n* History of malignancies other than non-small cell lung cancer in the past 5 years","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are:\n\n* How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer?\n* Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival?\n* Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?",[25,26,27],"Non-small Cell Lung Cancer","Minimal Residual Disease","Adaptive Treatment","RECRUITING","2025-04-08",{"date":31,"type":32},"2025-04-16","ACTUAL",{"date":34,"type":32},"2025-03-25",{"date":36,"type":19},"2028-07-31",{"name":38,"class":39},"Peking University People's Hospital","OTHER",""]